Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates.

Antiviral therapy - 1 Jan 2010

Verheyen Jens, Schweitzer Finja, Harrer Ellen G, Knops Elena, Mueller Sandra M, Däumer Martin, Eismann Kathrin, Bergmann Silke, Spriewald Bernd M, Kaiser Rolf, Harrer Thomas

Abstract excerpt

INTRODUCTION: HIV type-1 (HIV-1) protease (PR) and cleavage site (CS) mutations accumulate in protease-inhibitor-resistant isolates. HIV-1 CS mutation 431V is the most frequent treatment-associated CS mutation; however, little is known about its origin in treatment-naive HIV-1 isolates. Recently,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Multiple, Viral
Share to Epitopes, T-Lymphocyte

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to gag Gene Products, Human Immunodeficiency Virus

Share to HIV Infections

Share to HLA-B Antigens

Share to Protease Inhibitors

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 20834103
DOI: 10.3851/IMP1640

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-20834103-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of immune selection as a potential cause for the presence of cleavage site mutation 431V in treatment-naive HIV type-1 isolates.PMID 20834103Read ↗

Polymorphism of HIV type 1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors.Semantic proximity Read ↗

Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates.Semantic proximity Read ↗

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.Semantic proximity Read ↗

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.Semantic proximity Read ↗

Early selection of resistance-associated mutations in HIV-1 RT C-terminal domains across different subtypes: role of the genetic barrier to resistance.Semantic proximity Read ↗

Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease.Semantic proximity Read ↗

Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.Semantic proximity Read ↗

E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.Semantic proximity Read ↗

Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance.Semantic proximity Read ↗

The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.Semantic proximity Read ↗

Dynamics of gag-pol minority viral populations in naive HIV-1-infected patients failing protease inhibitor regimen.Semantic proximity Read ↗

Human immunodeficiency virus type 1 protease-correlated cleavage site mutations enhance inhibitor resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.